<DOC>
	<DOCNO>NCT01660061</DOCNO>
	<brief_summary>To Assess Influence Antiphospholipid Antibodies INR Test Results Patients Antiphospholipid Syndrome Anticoagulated Vitamin-K Antagonists .</brief_summary>
	<brief_title>Monitoring Anticoagulant Therapy Antiphospholipid Syndrome</brief_title>
	<detailed_description>Patients antiphospholipid syndrome receive Vitamin-K antagonist secondary prevention first thrombotic complication know high risk recurrent thrombotic event despite INR value therapeutic range . It ist also know antiphospholipid antibody interfere phospholipid-dependent test ( e.g . prothrombin time INR ) . The primary objective study determine prevalence interfere antiphospholipid antibody . The intensity anticoagulant therapy assess measure INR use different thromboplastin CoaguChek system INR self-assessment . Test result compare measurement phospholipid-independent chromogenic factor X . The second objective study evaluate incidence recurrent thrombotic event 1-year follow-up .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Antibodies , Antiphospholipid</mesh_term>
	<criteria>age 1890 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Antiphospholipid syndrome</keyword>
	<keyword>Antiphospholipid antibody</keyword>
	<keyword>Vitamin-K antagonist</keyword>
	<keyword>International normalize ratio</keyword>
	<keyword>Chromogenic factor X</keyword>
</DOC>